How will MVI meet its long-term goal of developing a malaria vaccine?
To ensure the development of P. falciparum vaccines with at least 80 percent efficacy against clinical malaria in children through age five and in pregnant women, MVI will: • Maintain a vaccine project portfolio with at least eight preclinical projects, at least four early clinical projects, and at least one late clinical project. • Complete RTS,S Phase 3 development activities to initial filing go/no-go decision. • Ensure all supported clinical evaluations are consistent with international standards. • Lead the development and maintenance of evaluation tools to comparatively assess candidate vaccines and better inform development decisions. • Consider practical aspects of vaccine supply, approval, and use during advanced clinical development. To ensure that P. falciparum malaria vaccines are available and affordable where needed, MVI will: • Lay the foundation for a competitive market environment for malaria vaccines. • Partner with developing country manufacturers to reduce costs. •
